4 1 wickergenform4_102502.txt FORM 4 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 [X] Check box if no longer subject of Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). ________________________________________________________________________________ 1. Name and Address of Reporting Person* Wicker Damion E. -------------------------------------------------------------------------------- (Last) (First) (Middle) c/o J.P. Morgan Partners, LLC 1221 Avenue of the Americas-40th Floor -------------------------------------------------------------------------------- (Street) New York New York 10020 -------------------------------------------------------------------------------- (City) (State) (Zip) ________________________________________________________________________________ 2. Issuer Name and Ticker or Trading Symbol Genomic Solutions Inc. ("GNSL") ________________________________________________________________________________ 3. IRS Identification Number of Reporting Person, if an Entity (Voluntary) ________________________________________________________________________________ 4. Statement for Month/Day/Year October 25, 2002 ________________________________________________________________________________ 5. If Amendment, Date of Original (Month/Day/Year) ================================================================================ 6. Relationship of Reporting Person to Issuer (Check all applicable) [_ Director [_] 10% Owner [_] Officer (give title below) [X] Other (specify below) Former Director ________________________________________________________________________________ 7. Individual or Joint/Group Filing (Check applicable line) [X] Form filed by one Reporting Person [_] Form filed by more than one Reporting Person ________________________________________________________________________________ ================================================================================ Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned ================================================================================

* If the Form is filed by more than one Reporting Person, see Instruction 4(b)(v). Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. (Print or Type Responses) (Over) (Form 4-07/99) FORM 4 (continued) Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) ================================================================================

Explanation of Responses: (1) Pursuant to a Merger Agreement between Genomic Solutions Inc. and HAG Acq. Corp., a wholly owned subsidiary of Harvard Bioscience, Inc., dated as of July 17, 2002, all outstanding shares of the Issuer were exchanged for shares of Harvard Bioscience, Inc. and cash at an exchange rate of .1017 to 1. Immediately prior to the merger, options for 3,284 shares were exercised at the stated exercised price of $0.37 per share. (2) The amounts shown represent the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners (SBIC), LLC ("JPM SBIC"), a portion of which may be deemed attributable to the reporting person because the reporting person is a managing director of JPM SBIC and a limited partner of the general partner of J.P. Morgan Partners (BHCA), L.P. (3) All options not exercised prior to the merger were cancelled upon consummation of the merger. (4) The reporting person was contractually obligated to exercise the options at the request of, and to transfer any shares issued under the stock options to, JPM SBIC. /s/ Damion E. Wicker 10/29/02 --------------------------------------------- ----------------------- Damion E. Wicker Date ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure.

GENOMIC SOLUTIONS INC 4